A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
The purpose of this study is to determine the effect of ixazomib maintenance therapy on
progression free survival (PFS) compared with placebo, in participants with newly diagnosed
multiple myeloma (NDMM) who have had a major response (complete response [CR], very good
partial response [VGPR], or partial response [PR]) to initial therapy and who have not
undergone stem-cell transplantation (SCT).
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society